FDA-APPROVED

Tirzepatide

The weight-loss drug that beat semaglutide head-to-head. Sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Here's what it actually is and what the trials showed.

The 30-second read

Tirzepatide is a weekly injection that does what GLP-1 drugs like Ozempic do, but it hits a second hormone receptor (GIP) at the same time. In big randomized trials, that translated into around 22% average weight loss over 18 months, the highest number in any approved weight-loss drug to date, and meaningfully more than semaglutide produced in a head-to-head study. It's FDA-approved as Mounjaro (for type 2 diabetes, 2022) and Zepbound (for weight management, 2023). It's prescription-only. The catch is the same as the rest of the class: GI side effects are common, the drug works while you take it and tends to lose ground when you stop, and the cost-and-access conversation is real.

Why this peptide is on people's radar

Tirzepatide arrived as the first drug in a new class, a "dual agonist" that activates both the GLP-1 and GIP hormone receptors. Eli Lilly developed it, the FDA approved it in 2022 for type 2 diabetes, and the conversation accelerated almost overnight when the SURMOUNT-1 trial showed mean weight loss around 22.5% in adults with obesity over 72 weeks.

The other reason it became unavoidable: in 2024, results from SURMOUNT-5, a head-to-head comparison with semaglutide (the active ingredient in Ozempic and Wegovy), were published in the New England Journal of Medicine. Tirzepatide produced about 20.2% mean weight loss over 72 weeks; semaglutide produced about 13.7%. That gap is enormous in clinical-trial terms, and it shifted how clinicians, patients, and the press talked about weight-loss medication. Coverage in the New York Times, STAT, and CNBC put real numbers in front of a general audience.

Beyond the weight figures, two other threads keep the conversation alive: type 2 diabetes outcomes (Mounjaro produced larger A1C reductions than other GLP-1 drugs in the SURPASS trials), and the access-and-cost conversation that has dominated 2025–2026, list prices in the four-figures-per-month range, insurance coverage that's inconsistent, and a compounding ecosystem that emerged to fill the gap and then partially collapsed as the FDA declared the shortage over.

What people are usually trying to do with it

Most people exploring tirzepatide are trying to do one of these:

Lose meaningful weight, the kind that diet and exercise alone hasn't moved
Manage type 2 diabetes with a drug that also tends to help with weight
Quiet down the constant "food noise", the pull-toward-the-fridge, can't-stop-thinking-about-snacks feeling
Lower long-term cardiovascular risk that comes along with obesity and diabetes
Avoid the regain cycle they've experienced with diet attempts in the past (with eyes open about what happens when the drug stops)

What the science actually shows

Tirzepatide is one of the better-studied weight-loss and diabetes drugs in recent memory. Here's a plain-English summary of what the trial data actually says.

Weight loss in adults with obesity

SURMOUNT-1 reported about 22.5% mean weight loss at the highest dose over 72 weeks in adults with obesity but without type 2 diabetes, the largest figure for any approved weight-loss medication.1

Better than semaglutide head-to-head

SURMOUNT-5, published in NEJM, compared tirzepatide directly against semaglutide. Mean weight loss at 72 weeks: 20.2% vs 13.7%. Statistically significant, clinically meaningful.2

Type 2 diabetes outcomes

Across the SURPASS trial program, tirzepatide produced larger reductions in A1C than other GLP-1 drugs in the comparator arms, plus weight loss as a bonus.3

Cardiovascular and metabolic markers

Trial data show improvements in blood pressure, triglycerides, and waist circumference. The SURMOUNT-MMO cardiovascular-outcomes trial is ongoing.4

What happens when people stop

SURMOUNT-4, the withdrawal trial, found that people who stopped tirzepatide regained a significant share of the weight they had lost. People who stayed on it kept losing.5

The honest read

What's solid:

This is one of the most rigorously demonstrated weight-loss drugs ever brought to market. The trial results are large, replicated, and head-to-head superior to the prior leading drug. For people who meet the prescribing criteria, the clinical case is strong.

What's still being worked out:

Long-term cardiovascular outcomes (the SURMOUNT-MMO trial is still running). What the right strategy is when people want to stop. How best to combine it with, or transition to, lifestyle interventions for sustained results. Real-world side-effect rates outside trial conditions.

What's hyped beyond the evidence:

Claims that tirzepatide is "easy" or has "no side effects." About a quarter of trial participants experienced GI side effects (nausea, diarrhea, vomiting) significant enough to be reported. Some discontinued for that reason. Also: the framing that this is a permanent fix, the withdrawal data suggests most people regain a meaningful portion of weight loss when they stop.

Things to know if you're looking into it

How it's used: a once-weekly subcutaneous injection (a thin needle into belly fat, thigh, or upper arm). Pre-filled pens make it self-administered after instruction.
Brand names: Mounjaro (FDA-approved for type 2 diabetes, May 2022) and Zepbound (FDA-approved for chronic weight management, November 2023). Same molecule, different label.
Prescription only: tirzepatide is a prescription drug. Compounded versions are not the same as the FDA-approved product, and the FDA-approved compounding pathway has narrowed considerably as Lilly's supply caught up.
Common side effects: nausea, diarrhea, decreased appetite, constipation, upper abdominal discomfort. Most are dose-dependent and improve as the body adjusts. Slow titration is the standard mitigation.
Cost and access: list prices are in the high-three-figures-to-four-figures per month range. Coverage varies widely by insurer and by indication (diabetes is more frequently covered than weight management).
Healthcare provider involvement: not optional. This is a prescription medication, dosing is gradually escalated under supervision, and screening for contraindications (history of medullary thyroid carcinoma, MEN2) is required.
Specific dosing schedule, mechanism, half-life, and trial detail: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

FDA-approved prescription drug. The approved product (Mounjaro® and Zepbound®) ships in pre-filled pens, not lyophilized vials — the calculator below is an educational reference for the molecule's dose math. Compounded tirzepatide is not the FDA-approved drug and operates outside the manufacturing oversight that comes with approval. This is not dosing guidance.

Suggested start

2.5 mg/week

FDA titration starts here for 4 weeks

Common range

5–15 mg/week

Approved maintenance: 5, 10, or 15 mg

Max dose

15 mg/week

FDA-approved ceiling

Cycle

Continuous

Under medical supervision

Vial size

Bacteriostatic water

mL

Defaults to a 5 mg/mL dilution (10 mg/mL on the 30 and 60 mg vials) — lower concentration gives more precision on the syringe at low doses. Adjust to taste.

Weekly dose

mg

Once-weekly subcutaneous injection. Approved doses: 2.5, 5, 7.5, 10, 12.5, 15 mg.

Concentration

5.0 mg/mL

Per dose

0.50 mL

50 units on insulin syringe

Doses per vial

~8

~8 weeks of weekly dosing

When to stay put vs. escalate

Stay put when GI side effects (nausea, vomiting, diarrhea, constipation) are present at all, when you've been at the current dose less than four weeks, or when the dose is producing the response you're after. The FDA labeling builds in a four-week minimum at each step for exactly this reason — tolerability and steady results are the signal to hold, not to push.

Consider escalating only after at least four weeks at the current dose, when GI effects have settled to baseline, when weight-loss progress has clearly plateaued, and when you have headroom toward your goal. Increments are 2.5 mg per step in the FDA schedule.

Don't stack steps. Skipping a 2.5 mg titration rung is the most reliable way to produce intolerable GI symptoms and discontinue treatment. The escalation pace exists because patients who titrate slowly stay on the medication; patients who jump rungs frequently don't.

For educational and research purposes only. This is not medical advice. Tirzepatide is a prescription medication; dosing should be set and supervised by a licensed healthcare provider. Compounded products are not the FDA-approved drug.

What people often ask

How is tirzepatide different from Ozempic?

Ozempic is semaglutide, which activates one hormone receptor (GLP-1). Tirzepatide activates two. GLP-1 and GIP. In the head-to-head trial, that translated into about 6.5 percentage points more weight loss on average. Both are weekly injections.

Is Mounjaro the same as Zepbound?

Same molecule, different label. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. Insurance generally treats them as separate drugs.

How much weight do people actually lose?

In SURMOUNT-1, average loss at the highest dose was about 22.5% of body weight over 72 weeks. Individual results vary widely; some people lose much more, some less.

Do you have to stay on it forever?

The SURMOUNT-4 withdrawal trial showed that people who stopped regained a meaningful share of the weight they had lost. So in practical terms, the drug works while you're taking it. What "long-term use" looks like is still being worked out.

What about the side effects?

The most common are GI: nausea, diarrhea, constipation, decreased appetite. They're usually worst right after a dose increase and tend to improve as your body adjusts. A small share of people stop the medication because of side effects.

Are compounded versions the same?

No. Compounded "tirzepatide" is not FDA-approved and isn't subject to the same manufacturing oversight. The FDA's stance on compounded GLP-1s has tightened significantly as the official supply has caught up with demand.

Who shouldn't take it?

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). It also requires caution in people with a history of pancreatitis, gallbladder disease, or severe GI disease. Your prescriber will screen for these.

FDA and regulatory status

Status as of May 5, 2026: FDA-approved as Mounjaro (May 2022) for adults with type 2 diabetes, and as Zepbound (November 2023) for chronic weight management in adults with obesity or overweight plus a related condition. Both formulations are administered as a once-weekly subcutaneous injection. Approved doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg. Approved internationally in the EU, UK, Canada, Australia, and Japan under the same names. Status updates land here when they happen.

Notable commentary

A few of the public conversations that have shaped how people think about tirzepatide. Editorial coverage and trial reporting, not clinical evidence on its own.

SURMOUNT-5 head-to-head coverage

When the SURMOUNT-5 head-to-head trial was published in NEJM, it received broad mainstream coverage that translated the trial's clinical numbers into everyday language for general readers.

Editorial coverage of clinical-trial results. For educational purposes only.

Want to go deeper? Mechanism, dosing schedule, half-life, full SURMOUNT/SURPASS trial detail, side-effect profile, and references. Click to expand.

Background and development

Tirzepatide is a 39-amino-acid synthetic peptide developed by Eli Lilly. It is the first FDA-approved drug to activate both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, the so-called "dual agonist" or "twincretin" class. Mounjaro received FDA approval for type 2 diabetes in May 2022. Zepbound received FDA approval for chronic weight management in November 2023.

Mechanism of action

Tirzepatide engages two distinct receptors that both contribute to glucose control and appetite regulation:

GLP-1 receptor activation

The same receptor activated by semaglutide. Triggers glucose-dependent insulin release, slows gastric emptying (which prolongs satiety), and acts in the central nervous system to reduce appetite and food intake.

GIP receptor activation

GIP also stimulates insulin release in the presence of glucose. The combined GLP-1 + GIP signal appears to produce additive (and possibly synergistic) effects on weight loss and glucose regulation, beyond what GLP-1 alone produces.

Half-life and dosing

Plasma half-life is approximately 5 days, supporting once-weekly subcutaneous administration. Steady-state is reached after roughly 4 weeks of consistent dosing.

FDA-approved dosing schedule

This is a prescription medication. Dosing is established by your prescriber based on the indication (diabetes vs. weight management), individual response, and tolerability.

Standard titration: start at 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. From there, doses can be increased in 2.5 mg increments at intervals of at least 4 weeks. Approved maintenance doses are 5, 10, and 15 mg, with 7.5 and 12.5 mg available as intermediate steps.

Slow titration is the primary tool for managing GI side effects.

The SURPASS and SURMOUNT trial programs

SURPASS, type 2 diabetes

Five Phase 3 trials evaluating tirzepatide versus placebo and active comparators (semaglutide 1 mg, basal insulin, others). Across the program, tirzepatide produced larger reductions in A1C than the comparator arms and significant weight loss as a secondary endpoint.

SURMOUNT, chronic weight management

The Phase 3 trial program for the weight-management indication. Selected results:

SURMOUNT-1: ~22.5% mean weight loss at 15 mg over 72 weeks in adults with obesity but without T2D.
SURMOUNT-2: 14.7% mean weight loss at 15 mg in adults with both T2D and obesity.
SURMOUNT-3: additional 21.1% weight loss after a 12-week intensive lifestyle phase, in patients who completed it.
SURMOUNT-4: withdrawal trial, patients who stopped tirzepatide regained substantial weight; those who continued kept losing.
SURMOUNT-5: head-to-head vs. semaglutide 2.4 mg. Tirzepatide 20.2% vs. semaglutide 13.7% mean weight loss at 72 weeks (NEJM, 2024).

Side effects and safety profile

The most common adverse events in clinical trials were gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, and upper abdominal pain. Most were mild-to-moderate and most improved with continued dosing. Approximately 4–7% of trial participants discontinued tirzepatide because of adverse events.

Boxed warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Additional warnings: pancreatitis, severe GI disease, gallbladder disease, hypoglycemia (especially in combination with insulin or sulfonylureas), acute kidney injury, hypersensitivity reactions, retinopathy progression in T2D, and risk of suicidal thoughts (per post-marketing surveillance).

References

Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." N Engl J Med, 387(3), 205–216. PubMed
Aronne LJ, Horn DB, le Roux CW, et al. (2024). "Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5)." N Engl J Med, 392(1), 26–37. PubMed
Frías JP, Davies MJ, Rosenstock J, et al. (2021). "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)." N Engl J Med, 385(6), 503–515. PubMed
Eli Lilly. (Ongoing). "SURMOUNT-MMO: Cardiovascular outcomes trial in adults with obesity." ClinicalTrials.gov NCT05556512. ClinicalTrials.gov
Aronne LJ, Sattar N, Horn DB, et al. (2024). "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)." JAMA, 331(1), 38–48. PubMed
U.S. Food and Drug Administration. "Mounjaro Prescribing Information." FDA.gov
U.S. Food and Drug Administration. "Zepbound Prescribing Information." FDA.gov

For educational and research purposes only. This is not medical advice. Tirzepatide is a prescription medication; this page does not provide dosing recommendations or substitute for evaluation by a licensed healthcare provider. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.